首页> 外文OA文献 >DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer
【2h】

DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer

机译:DNA甲基化调节剂介导的胃癌中的修饰模式和肿瘤微环境表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Growing evidence implies a link between DNA methylation and tumor immunity/immunotherapy. However, the global influence of DNA methylation on the characteristics of the tumor microenvironment and the efficacy of immunotherapy remains to be clarified. In this study, we systematically evaluated the DNA methylation regulator patterns and tumor microenvironment characteristics of 1,619 gastric cancer patients by clustering the gene expression of 20 DNA methylation regulators. Three gastric cancer subtypes that had different DNA methylation modification patterns and distinct tumor microenvironment characteristics were recognized. Then, a DNA methylation score (DMS) was constructed to evaluate DNA methylation modification individually. High DMS was characterized by immune activation status, increased tumor mutation burden, and tumor neoantigens, with a favorable prognosis. Conversely, activation of the stroma and absence of immune cell infiltration were observed in the low DMS group, with relatively poor survival. High DMS was also certified to be correlated with enhanced efficacy of immunotherapy in four immune checkpoint blocking treatment cohorts. In conclusion, the characterization of DNA methylation modification patterns may help to enhance our recognition of the tumor immune microenvironment of gastric cancer and guide more personalized immunotherapy strategies in the future.
机译:日益增长的证据意味着DNA甲基化和肿瘤免疫/免疫疗法之间的联系。然而,DNA甲基化对肿瘤微环境特征和免疫疗法疗效的全局影响仍然澄清。在这项研究中,通过聚类20dNA甲基化调节剂的基因表达,系统地评估了1,619例胃癌患者的DNA甲基化调节器模式和肿瘤微环境特征。识别出具有不同DNA甲基化改性模式和不同肿瘤微环境特征的三种胃癌亚型。然后,构建DNA甲基化评分(DMS)以单独评估DNA甲基化修饰。高DMS的特征在于免疫激活状态,增加肿瘤突变负担和肿瘤新抗原,具有良好的预后。相反,在低DMS组中观察到基质和不存在免疫细胞浸润的活化,生存率相对较差。高DMS还经认证与免疫检查点抑制治疗队列的四种免疫检查点增强疗效相关。总之,DNA甲基化改性模式的表征可能有助于提高我们对胃癌肿瘤免疫微环境的识别,并在将来引导更个性化的免疫疗法策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号